- Original Articles
- Open Access
Differences in Proteinase K Resistance and Neuronal Deposition of Abnormal Prion Proteins Characterize Bovine Spongiform Encephalopathy (BSE) and Scrapie Strains
Molecular Medicine volume 5, pages406–418(1999)
Prion diseases are associated with the accumulation of an abnormal isoform of host-encoded prion protein (PrPSc). A number of prion strains can be distinguished by “glycotyping” analysis of the respective deposited PrPSc compound. In this study, the long-term proteinase K resistance, the molecular mass, and the localization of PrPSc deposits derived from conventional and transgenic mice inoculated with 11 different BSE and scrapie strains or isolates were examined. Differences were found in the long-term proteinase K resistance (50 µg/ml at 37°C) of PrPSc. For example, scrapie strain Chandler or PrPSc derived from field BSE isolates were destroyed after 6 hr of exposure, whereas PrPSc of strains 87V and ME7 and of the Hessen1 isolate were extremely resistant to proteolytic cleavage. Nonglycosylated, proteinase K-treated PrPSc of BSE isolates and of scrapie strain 87V exhibited a 1–2 kD lower molecular mass than PrPSc derived from all other scrapie strains and isolates. With the exception of strain 87V, PrPSc was generally deposited in the cerebrum, cerebellum, and brain stem of different mouse lines at comparable levels. Long-term proteinase resistance, molecular mass, and the analysis of PrPSc deposition therefore provide useful criteria in discriminating prion strains and isolates (e.g., BSE and 87V) that are otherwise indistinguishable by the PrPSc “glycotyping” technique.
Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, are fatal infectious diseases affecting humans [Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheincker syndrome (GSS), fatal familial insomnia (FFI), and kuru], sheep, goats and mouflon (scrapie), cattle [bovine spongiform encephalopathy (BSE)], mink [transmissible mink encephalopathy], and deer [chronic wasting disease]. In the course of these diseases an isoform of cellular prion protein (PrPC) accumulates as a pathological prion protein (PrPSc) in the nervous and lymphatic systems (1–3). According to the prion theory, PrPSc itself constitutes the infectious agent (4). Host-encoded PrPC is widely expressed in neuronal cells as a cell-membrane protein with a molecular mass of 33–36 kD in a fully matured and diglycosylated form. Its physiological function is as yet unknown. In pulse-chase experiments on neuroblastoma cells (N2a cells) infected by the scrapie strain Chandler, PrPC had a half-life of less than 4 hr, whereas PrPSc was metabolically stable for 48 hr and longer (5). In contrast, PrPSc is distinguished from PrPC by physicochemical features: it forms insoluble aggregates, the scrapie-associated fibrils (SAFs), also termed prion rods (6–11). Furthermore, it is partially resistant to proteinase K digestion (4,12,13); for instance, proteinase K only cleaves off 60–70 residues (the exact number depends on the species and strain of agent) of the 211–221 residues encompassing the amino acid backbone of post-translationally processed PrPSc, leaving behind a resistant core fragment with a molecular mass of 27–30 kD, if in diglycosylated form. In contrast to PrPC, PrPSc contains a high β-sheet content (14–16).
A variety of different prion strains have been discovered that can be distinguished according to differences in their transmissibility, incubation time, induced clinical symptoms, brain lesions, and resistance to inactivation (17–24). Western blot analysis has revealed that nonglycosylated, proteinase K-treated PrPSc of the scrapie strain 87V and of the transmissible mink encephalopathy (TME) strain “Hyper” exhibit a 1–2 kD lower molecular mass than PrPSc accumulated during the infection of mice or hamsters with other scrapie or TME strains (25–26). Three different molecular masses of nonglycosylated CJD-derived PrPSc have been reported (27), whereby PrPSc derived from the new variant CJD (nvCJD) clusters into the category of low molecular mass (27). A low molecular mass was also reported for BSE-derived PrPSc. However, no data are as yet available on the molecular masses of mouse-passaged scrapie-derived PrPSc prions obtained from diseased individuals of the same host species.
Comparative analysis of glycoform ratios (nonglycosylated, monoglycosylated, and diglycosylated fraction of PrPSc) is another useful means for discriminating TSE strains (so-called glycotyping). In conventional cases of CJD, GSS, and kuru (27), as well as in mice infected with the scrapie strains Chandler and 79A, the monoglycosylated fraction is the major compound of PrPSc (28,29). In contrast, infections with the nvCJD, BSE, and scrapie strains 87V and 263K lead to the aberrant deposition of diglycosylated PrPSc (27–29).
Molecular analysis of the deposited PrPSc has thus provided important criteria for the discrimination of prion strains. It must be noted, however, that PrPSc produced in the course of infection by certain strains or isolates (e.g., BSE and 87V) are hardly distinguishable at all by the glycotyping technique. In the current study, we introduce further criteria for the characterization of strains or isolates. We were able to demonstrate that PrPSc resists the long-term exposure to proteinase K and followed this up by comparing the molecular mass of proteinase K-treated PrPSc of mouse-passaged BSE and scrapie strains, as well as by quantitatively analyzing the distribution of PrPSc deposits in different sites in the brain. The data presented here confirm the existence and distinctiveness of prion strains and underline the fact that BSE isolates can be distinguished from experimental and field scrapie strains or isolates by physicochemical analysis.
Materials and Methods
Propagation of BSE and Scrapie Strains
C57BL/6 mice were intracerebrally inoculated (20 µl of 1% mouse brain homogenate) with cloned mouse scrapie strains ME7, 22A, 79A, and 87V (kindly provided by M. Bruce, BBSRC & MRC Neuropathogenesis Unit, Edinburgh) and with the Chandler strain (kindly provided by C. Weissmann, University of Zürich). Similarly, VM95 mice (a gift from M. Bruce, BBSRC & MRC Neuropathogenesis Unit, Edinburgh) were inoculated with strains 87V and 22A. The Chandler strain was passaged in outbred white Swiss (CD1) mice and transgenic Tg20 mice [(29a) obtained from C. Weissmann] that overexpressed PrPC. The scrapie strain 263K (obtained from H. Diringer, Robert Koch Institute, Berlin) was used to infect Syrian hamsters. The Hessen1 isolate was derived from a field case of scrapie in a 4-year-old Suffolk ram (30) and was isolated and subpassaged in C57BL/6 mice. Isolates S833 and S540 from the brain of Suffolk sheep that had been naturally infected by scrapie were transmitted to C57BL/6 mice by primary passage. BSE strains isolated from cattle that had developed BSE in the United Kingdom (BSE-UK; courtesy of R. Bradley, Weybridge) and in Germany (BSE-G) were subpassaged in C57BL/6 and VM95 mice. To prevent mixing the strains by cross-contamination, all instruments for inoculation were porous-load autoclaved at 136°C and 3 bars for 4 hr prior to use and the animals were kept in isolation in facilities set up for this purpose for the respective scrapie strain. At the clinical stage of the disease, the animals were killed and their brains removed and stored at −20°C. Conservation of strain-specific characteristics were monitored by brain-lesion profile-scoring performed on indicator mice (data not shown). The measurement of the incubation period was calculated as the interval between inoculation and the well-defined appearance of typical symptoms of scrapie disease.
Preparation of Brain Homogenates and Purification of Prion Proteins (SAFs)
For each strain or isolate, separate brain homogenates from individual mice were examined separately and the pools contained brain tissues of several animals. Brain tissues were homogenized in phosphate-buffered saline (PBS) containing 0.5% NP-40 and 0.5% sodium deoxycholate (27) and were sonicated for 20–30 sec. Debris was removed by centrifugation at 2000 rpm for 5 min and supernatants [10% (w/v) homogenates] were stored at −20°C.
PrPSc was purified using a modified protocol as described previously (8). In summary, brain tissue was homogenized in brain lysis buffer (10 mM sodium phosphate containing 10% N-lauryl-sarcosinate, 3 mM phenylmethylsulfonylfluoride (PMSF), and 3 mM N-ethylmaleimide). Cell detritus was pelleted at 20,000 rpm for 5 min and in a further centrifugation step fibrils were pelleted at 100,000 rpm for 30 min. Pellets were resolubilized in 16 mM Tris buffer (pH 7.4) and incubated at 37°C. After 30 min, potassium iodide buffer (15% potassium iodide, 60 mM sodium thiosulfate 5-hydrochloride, 10 mM Tris buffer, pH 7.4) was added and samples were incubated for another 30 min at 37°C. After adding potassium iodide buffer (10%) to each sample, fibrillar structures were pelleted at 100,000 rpm for 30 min, supernatants were removed, and pellets were dried.
Treatment with Proteinase K and PNGaseF
To digest PrPSc of homogenates or SAFs, proteinase K (50 µg/ml) was added to the sample and incubation was carried out for 1 hr (37°C), unless otherwise indicated. Digestion was terminated by adding 5 mM PMSF (Boehringer Mannheim, Mannheim, Germany) and heating the samples at 95°C for 15 min. For deglycosylation, the proteinase K-treated samples were digested with 10 mU/ml PNGaseF (Boehringer, Mannheim) for 6 hr at 37°C. The reaction was terminated by heating to 95°C for 15 min and the samples were stored at −20°C.
Electrophoretic separation of proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a mini-slab-gel apparatus (Mini-protein II dual slab cell, Biorad, Munich) was performed with 16% or 20% polyacrylamide gels as previously described (31). Before loading onto the gels, the samples were suspended in SDS-loading buffer and heated to 95°C for 5 min. Proteins were electroblotted onto Immobilon-P membranes (Millipore, Bedford, MA) using a semi-dry blotting system (Biorad). Membranes were blocked in PBS containing 0.05% TWEEN 20 (PBST), 5% non-fat milk powder, and 5% fetal calf serum (FCS) and were incubated with a mouse-specific polyclonal anti-peptide rabbit antibody Ra5/7 at 1:2000 dilution in blocking buffer to detect mouse-passaged PrPSc antibody was raised to the amino terminus of mouse PrPSc (amino acids 95–110: THNQWNKPSKPKTNMK). To detect hamster-passaged PrPSc, the monoclonal antibody 3F4 was used at a dilution of 1:5000 in PBST. Horseradish peroxidase-conjugated affinity-purified goat anti-rabbit immunoglobulin G (IgG) or goat anti-mouse IgG (Dianova, Hamburg, Germany) served as the detection antibody. The membranes were developed using a chemiluminescence enhancement kit (ECL, Amersham, Little Chalfont, UK) and the protein bands were visualized on high-performance luminescence detection films (Hyperfilm ECL, Amersham).
Quantitative and Statistical Analysis
In order to glycotype the PrP strains or isolates, the banding intensities of the non-, mono-, and diglycosylated PrP isoforms were determined in the linear range of light emission, which was verified for each strain or isolate by analyzing serially diluted samples after digestion of PrPSc with proteinase K for 1 hr at 37°C, as previously described (29). The signal bands were scanned on a chemiluminescence photoimager (Fujifilm, Düsseldorf, Germany) with the CSC program. For quantification, the banding intensities of the non-, mono- and diglycosylated PrP isoforms were determined with the TINA2.0 program and calculated as described (32). For experiments determining long-term proteinase K resistance, signal intensities of digested pooled PrPSc (1 hr) were defined as 100% for each strain, respectively, and the percentages of long-term hydrolyses were calculated. Standard errors were calculated from the means of different gel runs. For the calculation of PrPSc deposits in different brain regions, identical amounts of each homogenate and of each individual animal were loaded onto the gels. Protein intensities of the investigated areas in an individual animal were determined and the deposits were calculated as percentages of the total signals. After separate SDS-PAGE and immunoblotting, the deposits were analyzed by calculating the means of each individual. The standard errors were assessed from the means of the animals for each PrP banding pattern to analyze the differences among individuals. To exclude variations in the separations in different SDS-PAGE runs, each brain homogenate was electrophoresed, immunoblotted, and scanned at least four times. Relative PrPSc amounts of different scrapie and BSE strains or isolates were determined by photoimager recording of immunoblot signals’ combined values of all three glycoforms. Standard error values were calculated from means of the gels runs of the individual animals tested.
In the current study, six phenotypically well-defined rodent scrapie strains (87V, 79A, Chandler, 22A, ME7, 263K) as well as five mouse-passaged field BSE (BSE-G and BSE-UK) and scrapie (Hessenl, S833, and S540) isolates were propagated in at least one out of four different conventional or transgenic mouse lines or in Syrian hamsters (Table 1). All strains and isolates led to the typical characteristics of scrapie disease after unique incubation times in the animals, which formed one basis for their discrimination. PrPSc molecules accumulated in the neuronal systems were subsequently analyzed with respect to their glycosylation patterns after proteinase K digestion.
Long-Term Resistance of PrPSc to Proteinase K
Abnormal PrP (PrPSc) was purified from brain tissue samples of the infected mice and hamsters by standard procedures established for the preparation of scrapie-associated fibrils. Fibrils were subsequently exposed for prolonged times (1, 3, 6, 24, and 48 hr) to proteinase K (50 µg/ml) to determine their relative proteolytic stability. Non-degraded PrPSc compounds were visualized as immunoblots using an antiserum to the amino terminus of the proteinase K-resistant PrPSc and residual antigen amounts quantified using enhanced chemiluminescence and photoimager techniques. In this set of experiments, banding signal intensities of PrPSc after digestion with proteinase K for 1 hr were defined as 100% for each strain or isolate. PrPC was proteolytically degraded entirely in this process. To minimize artefacts, all experiments were performed in duplicate and each sample was run on SDS-PAGE gels, immunoblotted, and analyzed in quadruplicate. To exclude specific effects arising from the mouse line involved, all BSE and scrapie strains (except 87V and 263K) used in this experiment were propagated in C57BL/6 mice. Most interestingly, PrPSc did not show a uniform resistance to proteinase K treatment (Figs. 1A, B, 2). PrPSc antigenicity of scrapie strain Chandler in C57BL/6 mice was degraded by as much as 84% after only 6 hr of exposure, whereas PrPSc of strain 87V was reduced by only 19% under identical conditions. Strain ME7 exhibited a similar proteinase K resistance to 87V with a reduction of PrPSc amounting to as little as 17% (Fig. 1A). The strains 22A and 263K had intermediate proteinase K resistance. PrPSc of 22A was decreased by 66% and PrPSc of 263K was reduced by 36%. However, an initially low proteinase K degradation rate did not automatically indicate that PrPSc resisted proteolytic cleavage to the same relative degree for extended times. After 48 hr of proteinase K exposure, the degree of PrPSc degradation of strains 87V, ME7, Chandler, 22A, and 263K was 86%, 94%, 99%, 88%, and 57%, respectively (Figs. 1A, 2). Thus, PrPSc of strain 263K was highly stable to extended proteinase K exposure (even beyond 72 hr of exposure; data not shown).
PrPSc from field isolates of scrapie, retrieved, and passaged in C57BL/6 mice was as disparate in long-term proteinase K stability as that from the defined BSE and scrapie strains (Fig. 1B). While over 90% of PrPSc from isolate S540 was diminished after 6 hr of incubation, the Hessen1 PrPSc isolate was almost entirely proteinase K-resistant. Scrapie isolate S833 along with the BSE isolates showed intermediate susceptibility (34% reduction after 6 hr of exposure). PrPSc of BSE-G and BSE-UK was degraded by 80% and 63%, respectively, after 6 hr of exposure.
In a second set of experiments, the influence of the different mouse lines used for propagation of TSE agents was analyzed. C57BL/6, CD1, and Tg20 carry the mouse prion allele Prnpa in homozygous form, while VM95 mice harbor the Prnpb allele. No effect of the mouse line used for propagation was observed for the BSE-G isolate or for the scrapie strain Chandler. However, a slight, yet statistically significant difference in long-term proteinase K resistance was found in PrPSc of scrapie strain 22A propagated in VM95 or C57BL/6 mice. This was all the more remarkable, as all PrPSc displayed strain-specific glycotyping patterns independent of the mouse type in which they were tested (data not shown). Thus, depending on the prion strain, the mouse line used as PrPSc source may have an effect, albeit minor, on its long-term proteinase K stability (Fig. 3).
Molecular Mass of PrPSc after Proteinase K Cleavage
Proteinase K-treated brain homogenates of mice infected with strains BSE, 87V, 22A, Hessen1, Chandler, and 79A were run on high-resolution SDS-PAGE gels and PrPSc bands were visualized by immunoblotting. As expected, the molecular mass of nonglycosylated PrPSc in almost all strains averaged 21 kD (Fig. 4). However, as previously described (25), PrPSc of strain 87V was cleaved by proteinase K to a 1–2 kD smaller fragment (molecular mass approximately 19 kD). As already demonstrated by the comparison of PrPSc produced in different species, the same characteristic could now be observed for both mouse-passaged BSE isolates: nonglycosylated proteinase K-degraded PrPSc molecules from mouse-passaged BSE isolates exhibited a lower molecular mass than those from the other scrapie strains. This difference was independent of mouse line (C57BL/6 or VM95 mice) used for propagation of BSE PrPSc.
Relative Amounts of PrPSc Deposits
Relative amounts of PrPSc deposits induced by the infection of mice with different prion strains or isolates were determined by photoimager recording of immunoblot signals (combined values of all three glycoforms). The most abundant PrPSc accumulation was found in C57BL/6 mice infected with the scrapie isolate Hessen1, which was thus set at 100% (Fig. 5). Similarly, pronounced accumulation levels were also observed in C57BL/6 mice infected with the mouse-adapted strain ME7 (Fig. 5). Intermediate PrPSc accumulation levels were found in C57BL/6 mice infected by 22A, 79A, Chandler, BSE-G, and BSE-UK. Interestingly, the levels of PrPSc produced were dependent of the respective mouse line used. PrPSc accumulation levels of all strains were lower in VM95 mice. Moreover, the neuronal overexpression of mouse PrPC in transgenic Tg20 mice (a factor of 10) did not give rise to elevated PrPSc amounts after inoculation with Chandler strain. Rather, PrPSc levels were eight times higher in C57BL/6 and five times higher in CD1 than in Tg20 mice.
Distribution of PrPSc Deposits
Consistent differences among the TSE strains were also observed with regard to the localization of PrPSc deposits in the brains of scrapie- and BSE-diseased mice (Fig. 6). In VM95 mice infected with either scrapie strain 87V or with BSE, PrPSc was accumulated largely in the brain stem. Interestingly, both BSE isolates exhibited the same deposition pattern in VM95 mice. In contrast, infection with strain 22A led to major PrPSc deposits in the cerebellum. Scrapie isolates Hessen1 and S833 differed in PrPSc distribution in the brain. Whereas PrPSc of Hessen1 accumulated largely in the brain stem, major PrPSc deposits of S833 were detected in the cerebellum, as with strain 22A.
There is a growing need to establish criteria for distinguishing TSE agents. Variations among scrapie, BSE, and CJD strains and isolates were detected by the glycotyping technique (27–29), but this technique does not discriminate every individual strain. In the present work, we have selected a number of biochemical and biological markers of PrPSc, which have not yet been studied in detail for their application in BSE and scrapie strains and isolates; as it turned out, these markers are useful in distinguishing prion strains more precisely.
We have analyzed the long-term proteinase K resistance, molecular mass of PrPSc, and topology and quantity of the PrPSc deposits. Our results demonstrate that PrPSc proteins of different BSE and scrapie strains consistently display differences in their long-term proteinase K resistance. For example, PrPSc of 87V and ME7 were relatively stable to proteinase K hydrolysis for up to 24 hr of digestion, whereas PrPSc of the Chandler strain was almost completely destroyed after as little as 6 hr of exposure. PrPSc of scrapie strains 22A and 263K displayed intermediate resistance. Interestingly, field scrapie isolates in mice were not as diverse as experimental scrapie strains. While the Hessen 1 isolate PrPSc was almost totally proteinase K-resistant, PrPSc of isolates S833 and S540 exhibited intermediate and high sensitivity to this enzyme. In comparison to most other scrapie strains, PrPSc of the BSE isolates exhibited intermediate resistance to proteinase K digestion. Scrapie strain 87V and strains of BSE exhibited a very similar pattern of signal intensities of the non-, mono- and diglycosylated PrPSc isoform (29) but after long-term proteinase K treatment, both strains could be clearly distinguished, BSE PrPSc being markedly less stable.
Our results are not unprecedented; strain-specific differences in the proteinase K stability of PrPSc compounds have already been observed. Kascsak et al. (25) exposed fibril preparations from scrapie strains 263K, 139A, and ME7 to proteinase K and separated the proteins on SDS-PAGE gels. In these experiments, the three typical bands were weaker in varying degrees, indicating that PrPSc of strain 139A was less resistant to proteinase K digestion than PrPSc of scrapie 263K and ME7. Later, similar differences were observed for transmissible mink encephalopathy strains Hyper and Drowsy, the latter being less resistant to proteinase K treatment (26).
The species and particular breed used for the generation of PrPSc may have an influence on its molecular characteristics. We compared PrPSc generated in a variety of different mouse lines carrying prion alleles Prnpa or Prnpb. These encode mouse PrP differing by polymorphisms at amino acids 108 (Leu/Phe) and 189 (Thr/Val) (33). According to our results, the effect of these polymorphisms on the long-term proteinase K resistance of PrPSc is not entirely clear. While no differences were found in long-term proteinase K resistance of PrPSc from the BSE-G isolate propagated in homozygous Prnpa C57BL/6 mice and Prnpb VM95 mice, PrPScs of scrapie strain 22A propagated in these two different mouse lines were distinct from another. It has been reported that SAF proteins from scrapie strains ME7 and 87V isolated from different mouse Unes differed in sensitivity to proteinase K (34), a result which contradicts that of another study that found no differences between strains 139A and ME7 (35).
The close linkage between PrPSc and the infectious agent itself is indisputable. It would seem that the strain-specific characteristics of prion diseases are brought about, if not encoded, by differences in the PrPSc conformations. Evidence for different conformations of several PrPSc strains has been demonstrated recently through use of a highly sensitive conformation-dependent immunoassay. Several hamster-passaged PrP strains differed in their conformation and each strain exhibited a distinct pattern (36). The underlying mechanisms for these strain-specific PrPSc conformations are still unclear—either these differences are solely due to variations in structure and conformation of PrPSc or to post-translational modifications of PrP.
Another unique characteristic of PrPSc from BSE isolates independent of the mouse line used is that proteinase K-treated PrPSc possesses a 1–2 kD lower molecular mass compared to similarly treated PrPSc of other experimental scrapie strains. The same characteristic was revealed for scrapie strain 87V PrPSc. However, none of the three German field isolates of scrapie included in this study induced the accumulation of proteinase K-treated PrPSc with such low molecular mass. Similar differences in the molecular mass of prion proteins were found for scrapie, as well as for BSE and human diseases such as CJD and FFI (27,34,37). A conformational change of strain-specific PrPSc could be one reason for differences in molecular mass, by additional N-terminal amino acids to proteinase K digestion. In addition to mouse lesion profile-scoring (38) and PrPSc glycotyping, this characteristic of BSE-derived PrPSc might therefore provide us with the first distinctive parameter for future discrimination of BSE and scrapie infections in small ruminants.
Total PrPSc amounts were determined in proteinase K-digested homogenates of mouse brain tissues. High levels were found in C57BL/6 mouse brains infected with the scrapie isolate Hessen1 and strain ME7, respectively, and the lowest levels were detected in transgenic Tg20 mice infected with Chandler. The formed PrPSc amounts differed in scrapie strains as well as in the mouse line used. In this way, we were able to recognize an influence according to the mouse line used. VM95 mice expressed less PrPSc than C57BL/6 mice independent of the strain.
We compared the levels of PrPSc accumulation in the cerebrum, cerebellum, and brain stem of diseased mice. Substantial differences in the distribution of the PrPSc deposits in these brain areas were found depending on the nature of the strain or isolate. By this criterion, scrapie strain 87V could be distinguished from all other prion strains, including BSE isolates. While strain 87V PrPSc is deposited most abundantly in the brain stem, BSE infection leads to a rather even range of PrPSc deposits in the brain stem, cerebellum, and cerebrum. PrPSc of strain 22A is deposited primarily in the cerebellum of the mice. These results are in agreement with histoblot results on strain 22A mouse brains, with predominant PrPSc staining in the cortex, granular cell layer of the cerebellum, hippocampus, and hypothalamus. Most PrPSc of 87V accumulated in the thalamus, locus ceruleus, and raphe nuclei of the brain stem; very few accumulated in the neocortex, hippocampus, and hypothalamus (39–40).
The inoculation of field agents of scrapie into C57BL/6 mice resulted in clearly different patterns. Each isolate had a specific incubation time, a particular amount of formed PrPSc, a characteristic distribution of PrPSc deposits in brain areas, and a characteristic resistance to proteinase K digestion. Scrapie isolate S833 exhibited properties similar to those of strain 22A with regard to proteinase K resistance and PrPSc deposition in brain. This finding suggests that 22A is a representative field strain of scrapie. Moreover, PrPSc glycotyping profiles, molecular mass, and/or long-term PK resistance results obtained indicated that the three German field isolates of scrapie can be distinguished from the BSE isolates.
In summary, these studies have demonstrated that the PrPSc elicited by distinct prion strains and isolates passaged in in- and outbred mouse lines has different but unique, strain-specific properties. Glycotyping of the non-, mono- and diglycosylated PrPSc isoforms, as well as analysis of the molecular mass of the protein bands, was not sufficient for providing a clear discrimination of some strains, such as scrapie strain 87V and the BSE isolates. Through differences in long-term resistance to proteinase K digestion, we were able to pinpoint a characteristic that helped us distinguish between these two strains/isolates. Analysis of the deposits and physicochemical characterization of PrPSc in BSE and scrapie strains/isolates thus yield important information for the possible discrimination between strains. Furthermore, it seems that PrPSc strains differ in their structural conformation; this can result in different proteinase K sensitivities, varying PrPSc accumulations, deposition in different brain areas, and individual glycoform patterns.
Bendheim PE, Barry RA, DeArmond SJ, Stites DP, Prusiner SB. (1984) Antibodies to a scrapie prion protein. Nature 310: 418–421.
DeArmond SJ, McKinley MP, Barry RA, Braunfeld MB, McColloch JR, Prusiner SB. (1985) Identification of prion amyloid filaments in scrapie-infected brain. Cell 41: 221–235.
Kitamoto T, Tateishi J, Tashima T, et al. (1986) Amyloid plaques in Creutzfeldt-Jakob disease stain with prion protein antibodies. Ann. Neurol. 20: 204–208.
Prusiner SB. (1991) Molecular biology of prion diseases. Science 252: 1515–1522.
Caughey B, Kocisko D, Priola SA, et al. (1996) Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. In: Baker HF, Ridley RM (eds). Methods in Molecular Medicine: Prion Diseases. Humana Press, Totowa, NJ, pp. 285–299.
Merz PA, Somerville RA, Wisniewski HM, Iqbal K. (1981) Abnormal fibrils from scrapie-infected brain. Acta Neuropathol. 54: 63–74.
Prusiner SB, Bolton DC, Groth DF, Bowman KA, Cochran SP, McKinley MP. (1982) Further purification and characterization of scrapie prions. Biochemistry 21: 6942–6950.
Diringer H, Gelderblom H, Hilmert H, Ozel M, Edelbluth C, Kimberlin RH. (1983) Scrapie infectivity, fibrils and low molecular weight protein. Nature 306: 476–478.
Prusiner SB, McKinley MP, Bowman KA, et al. (1983) Scrapie prions aggregate to form amyloid-like birefrigent rods. Cell 35: 349–358.
Barry RA, McKinley MP, Bendheim PE, Lewis GK, DeArmond SJ, Prusiner SB. (1985) Antibodies to the scrapie protein decorate prion rods. J. Immunol. 135: 603–613.
Bode L, Pocchiari M, Gelderblom H, Diringer H. (1985) Characterization of antisera against scrapie-associated fibrils (SAF) from affected hamster and cross-reactivity with SAF from scrapie-affected mice and from patients with Creutzfeldt-Jakob disease. J. Gen. Virol. 66: 2471–2478.
Bolton DC, McKinley MP, Prusiner SB. (1982) Identification of a protein that purifies with the scrapie prion. Science 218: 1309–1311.
Oesch B, Westaway D, Walchli M, et al. (1985) A cellular gene encodes scrapie PrP 27–30 protein. Cell 40: 735–746.
Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS. (1991) Secondary structure analysis of the scrapie associated protein PrP 27–30 in water by infrared spectroscopy. Biochemistry 30: 7672–7680.
Pan KM, Baldwin M, Nguyen J, et al. (1993) Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. U.S.A. 90: 10962–10966.
Safar J, Roller PP, Gajdusek DC, Gibbs CJ Jr. (1993) Conformational transition, dissociation, and unfolding of scrapie amyloid (prion) protein. J. Biol. Chem. 268: 20276–20284.
Dickinson AG, Meikle VMH. (1971) Host-genotype and agent effects in scrapie incubation: change in allelic interaction with different strains of agent. Mol. Gen. Genet. 112: 73–79.
Dickinson AG. (1976) Scrapie in sheep and goats. In: Kimberlin RH (ed). Slow Virus Diseases of Animals and Man. North-Holland, Amsterdam, pp. 209–241.
Dickinson AG, Taylor DM. (1978) Resistance of scrapie to decontamination. N. Engl. J. Med. 299: 1413–1414.
Fraser H. (1979) Neuropathology of scrapie: the precision of the lesions and their diversity. In: Prusiner SB, Hadlow WJ (eds). Slow Transmissible Diseases of the Nervous System, Vol. 1. Academic Press, New York, pp. 387–406.
Kimberlin RH, Walker CA, Millson GC, et al. (1983) Disinfection studies with two strains of mouse-passaged scrapie agent. J. Neurol. Sci. 59: 355–369.
Bruce ME, Dickinson AG. (1987) Biological evidence that scrapie agent has an independent genome. J. Gen. Virol. 68: 78–89.
Kimberlin RH, Walker CA, Fraser H. (1989) The genomic identity of different strains of mouse scrapie is expressed in hamsters and preserved on reisolation in mice. J. Gen. Virol. 70: 2017–2025.
Bruce ME, McConnell I, Fraser H, Dickinson AG. (1991) The disease characteristics of different strains of scrapie in SINC congenic mouse lines: implications for the nature of the agent and host control of pathogenesis. J. Gen. Virol. 72: 595–603.
Kascsak RJ, Rubenstein R, Merz PA, Carp RI, Wisniewski HM, Diringer H. (1985) Biochemical differences among scrapie-associated fibrils support the biological diversity of scrapie agents. J. Gen. Virol. 66: 1715–1717.
Bessen RA, Marsh RF. (1992) Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J. Virol. 66: 2096–2101.
Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. (1996) Molecular analysis of prion strain variation and the aetiology of “new variant” CJD. Nature 383: 685–690.
Somerville RA, Chong A, Mulqueen OU, Birkett CR, Wood SCER, Hope J. (1997) Biochemical typing of scrapie strains. Nature 386: 564.
Kuczius T, Haist I, Groschup MH. (1998) Molecular analysis of bovine spongiform encephalopathy and scrapie strain variation. J. Infect. Dis. 178: 693–699.
Fischer M, Rülicke T, Raeber A, et al. (1996) Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 15: 1255–1264.
Groschup MH, Weiland F, Straub OC, Pfaff E. (1996) Detection of scrapie agent in the peripheral nervous system of a diseased sheep. Neurobiol. Dis. 3: 191–195.
Groschup MH, Langeveld J, Pfaff E. (1994) The major species specific epitope of prion protein of ruminants. Arch. Virol. 136: 423–431.
Campbell RC. (1971) Statistische Methoden für Biologie und Medizin. Georg Thieme, Stuttgart.
Westaway D, Goodman PA, Mirenda CA, McKinley MP, Carlson GA, Prusiner SB. (1987) Distinct prion proteins in short and long scrapie incubation period mice. Cell 51: 651–662.
Kascsak RJ, Rubenstein R, Carb RI. (1991) Evidence for biological and structural diversity among scrapie strains. In: Chesebro BW (ed). Transmissible Spongiform Encephalopathies. Current Topics in Microbiology and Immunology. Springer-Verlag, Berlin, pp. 139–152.
Bockman JM, Kingsbury DT. (1988) Immunological analysis of host and agent effects on Creutzfeldt-Jakob disease and scrapie prion proteins. J. Virol. 62: 3120–3127.
Safar J, Wille H, Itri V, et al. (1998) Eight prion strains have PrPSc molecules with different conformations. Nat. Med. 4: 1157–1165.
Telling GC, Parchi P, DeArmond SJ, et al. (1996) Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274: 2079–2082.
Bruce ME, Chree A, McConnell I, Foster J, Pearson G, Fraser H. (1994) Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and species barrier. Philos. Trans. R. Soc. Lond. B 343: 405–411.
Taraboulos A, Jendroska K, Serban D, Yang S-L, DeArmond SJ, Prusiner SB. (1992) Regional mapping of prion proteins in brains. Proc. Natl. Acad. Sci. U.S.A. 89: 7620–7624.
Carlson GA. (1996) Prion strains. In: Prusiner SB (ed). Prions Prions Prions. Springer-Verlag, Berlin, pp. 35–47.
We thank Roswitha Fischer for her excellent technical assistance. This work was supported in part by grants from the Bundesministerium für Ernährung, Landwirtschaft und Forsten, the Bundesministerium für Bildung, Wissenschaft und Technologie, and the EU Commission.
Communicated by C. Weissmann.
About this article
Cite this article
Kuczius, T., Groschup, M.H. Differences in Proteinase K Resistance and Neuronal Deposition of Abnormal Prion Proteins Characterize Bovine Spongiform Encephalopathy (BSE) and Scrapie Strains. Mol Med 5, 406–418 (1999). https://doi.org/10.1007/BF03402129